GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (NAS:AZTA) » Definitions » EV-to-EBIT

Azenta (Azenta) EV-to-EBIT : -34.67 (As of May. 21, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Azenta EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Azenta's Enterprise Value is $2,028.2 Mil. Azenta's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-58.5 Mil. Therefore, Azenta's EV-to-EBIT for today is -34.67.

The historical rank and industry rank for Azenta's EV-to-EBIT or its related term are showing as below:

AZTA' s EV-to-EBIT Range Over the Past 10 Years
Min: -1902.02   Med: -40.57   Max: 636.48
Current: -34.67

During the past 13 years, the highest EV-to-EBIT of Azenta was 636.48. The lowest was -1902.02. And the median was -40.57.

AZTA's EV-to-EBIT is ranked worse than
100% of 457 companies
in the Medical Devices & Instruments industry
Industry Median: 20.17 vs AZTA: -34.67

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Azenta's Enterprise Value for the quarter that ended in Mar. 2024 was $2,544.6 Mil. Azenta's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-58.5 Mil. Azenta's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -2.30%.


Azenta EV-to-EBIT Historical Data

The historical data trend for Azenta's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azenta EV-to-EBIT Chart

Azenta Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -38.77 -86.59 -159.31 -316.92 -63.92

Azenta Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.41 -29.21 -63.92 -42.71 -43.50

Competitive Comparison of Azenta's EV-to-EBIT

For the Medical Instruments & Supplies subindustry, Azenta's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Azenta's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Azenta's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Azenta's EV-to-EBIT falls into.



Azenta EV-to-EBIT Calculation

Azenta's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2028.212/-58.5
=-34.67

Azenta's current Enterprise Value is $2,028.2 Mil.
Azenta's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Azenta  (NAS:AZTA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Azenta's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-58.5/2544.59692
=-2.30 %

Azenta's Enterprise Value for the quarter that ended in Mar. 2024 was $2,544.6 Mil.
Azenta's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Azenta EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Azenta's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Azenta (Azenta) Business Description

Traded in Other Exchanges
Address
200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
Executives
Herman Cueto officer: EVP, Chief Financial Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Violetta Hughes officer: VP, Chief Accounting Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
David C Gray officer: Chief Strategy & New Business C/O GT SOLAR INTERNATIONAL, INC., 243 DANIEL WEBSTER HIGHWAY, MERRIMACK NH 03054
Joseph R Martin director
Dorothy E Puhy director DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Mitchell Coyne officer: SVP and GM, Life Sciences Proj 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Ginger Zhou officer: SVP and General Manager, Genom 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Matthew Mcmanus officer: EVP & Chief Operating Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Lindon G Robertson officer: EVP & Chief Financial Officer C/O GRAFTECH INTERNATIONAL LTD., 12900 SNOW ROAD, PARMA OH 44130
Kimberly Crowley officer: Chief Human Resources Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Vandana Sriram officer: VP, Finance & Corp. Controller 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jesus Linda De officer: Chief Commercial Officer, LS 15 ELIZABETH DRIVE, CHEMSFORD MA 01824
David Jarzynka officer: Sr. VP, General Manager 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Robin Vacha officer: SVP, GM BLS-Products 15 ELIZABETH DRIVE, 15 ELIZABETH DRIVE, CHELMSFORD MA 01824